Clinical Trials in Maryland

Showing 541-560 of 19,983 trials

Nicotinic Receptor Genetic Variation and Alcohol Reward

NCT03294460

Background: People with the brain disease AUD (alcohol use disorder) have a serious problem with drinking. Researchers want to study how different people react to alcohol, and how genes affect this. They will focus on a nicotine receptor gene that may increase a person s AUD risk. Objectives: To see if people with variations of a nicotine receptor gene take alcohol differently and have different brain responses to alcohol cues. Eligibility: Healthy adults ages 21 - 60. This study includes smokers and non-smokers. Design: Participation will be based on evaluation under the NIAAA natural history protocol (14-AA-0181) or a screening visit under this protocol. Participants will have two 9-hour visits. They must have no alcohol or non-prescription drugs before all visits and no food or drink before the first visit. At every visit, participants will: * Get a light meal * Have breath and urine tests * Get taxi rides there and back At visits 1, participants will: * Have a thin plastic tube inserted in an arm and connected to a pump for alcohol infusion. * Have sensors on their chest to monitor heart rate. * Sit in a chair for 2.5 hours and get alcohol by pushing a button. Their breath alcohol level will be monitored. * Answer questions about mood and effects of alcohol * Give blood samples * Relax at the clinic while their breath alcohol level drops At visit 2, participants will: * Answer questions and do computer tests * Have an alcoholic drink and a snack * Have a magnetic resonance imaging (MRI) scan. They will lie in a machine that takes pictures of the brain. They will do computer tasks. * Have another drink and snack * Relax until their alcohol level drops Participants will have a follow-up call after each visit.

Alcohol Drinking

National Institute on Alcohol Abuse and Alcoholism (NIAAA)128 participantsStarted Jun 2019

Bethesda, Maryland, United States

RECRUITINGNA17 miles

NSS Grocery Store Brazil

NCT07249008

The purpose of this study is to assess the impact of non-sugar sweeteners (NSS) front-of-package labels (FOPL) on Brazilian parents' food and beverage selections for their children. The study includes three arms: 1. no NSS FOPL control group, 2. a group exposed to a NSS FOPL modeled after the Mexican warning label for NSS, and 3. a group exposed to a NSS FOPL using the magnifying glass symbol currently implemented in Brazil for nutrients of public health concern. Participants will be instructed to select products for their child, including one yogurt, three beverages (for breakfast, lunch, and dinner), one granola, and one cereal bar.

Control GroupMexico-based NSS FOPLBrazil-based NSS FOPL

George Washington University1,068 participantsStarted Feb 2026

Washington D.C., District of Columbia, United States

Nicotinic Receptor Genetic Variation and Alcohol Reward

NSS Grocery Store Brazil

Find Trials by Condition in Maryland

Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene

Examination of Nociscan Impact on Discogenic Low Back Pain Surgical Outcomes

Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder

Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma

Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer

EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

A Post-Market Clinical Evaluation of the Treatment of Femur Fractures With the Femoral Nail GT

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)

A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer

ITIL-306 in Advanced Solid Tumors

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.

A Phase 1 Study of IM-1021 in Participants With Advanced Cancer

A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)